UroGen Pharma
URGN
161 hedge funds and large institutions have $879M invested in UroGen Pharma in 2025 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 48 increasing their positions, 46 reducing their positions, and 23 closing their positions.
226% more call options, than puts
Call options by funds: $36.2M | Put options by funds: $11.1M
61% more capital invested
Capital invested by funds: $545M → $879M (+$333M)
48% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 23
8.74% more ownership
Funds ownership: 86.32% → 95.05% (+8.7%)
7% more funds holding
Funds holding: 150 → 161 (+11)
4% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 46
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$75.7M |
| 2 |
Millennium Management
New York
|
+$15.7M |
| 3 |
D.E. Shaw & Co
New York
|
+$15.5M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$12.9M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$27M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.4M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$7.99M |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$7.43M |
| 5 |
Citigroup
New York
|
-$6.83M |
URGN Hedge Fund Activity: Q3 2025 in Review
161 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2025, worth a combined $879M — up 61% from $545M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new URGN positions and 23 closed out — a net gain of 11 holders — while 48 added to existing stakes and 46 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $75.7M. The largest seller was Soleus Capital Management, cutting an estimated $27M.
- 161 institutional investors held UroGen Pharma (URGN) as of Q3 2025, up from 150 in Q2 2025.
- Funds reported $879M of UroGen Pharma stock for Q3 2025, up 61% quarter-over-quarter.
- 34 funds opened new UroGen Pharma positions in Q3 2025 and 23 closed out, a net change of +11 holders.
- The largest UroGen Pharma buyer in Q3 2025 was Paradigm Biocapital Advisors, an estimated $75.7M added.
- The largest UroGen Pharma seller in Q3 2025 was Soleus Capital Management, an estimated $27M sold.
Based on aggregated 13F filings for Q3 2025.